menu
    • menu

    Company profile for Milla Pharmaceuticals

    NEW Drugs in Dev: 3
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Milla Pharmaceuticals is engaged in the development, licensing / acquisition and commercialization of generic prescription drugs for the U.S. market focused on niche injectable and solution products for hospitals and clinics. Our goal is to deliver high quality medicines; via a world-class supply chain, at affordable prices by leveraging global partnerships with FDA-approved manufacturing facilities from around the world.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Milla PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    601 Carlson Parkway Suite 1050 Minnetonka, Minnesota 55305
    Telephone
    Telephone
    1 (833) 251 8463
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://millapharmaceuticals.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Paris Packaging Week

    Paris Packaging Week

    Not Confirmed

    envelop Contact Supplier

    Paris Packaging Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    A.forall Launch Direct Sales of Sodium Acetate Injection 2mEq/mL
    A.forall Launch Direct Sales of Sodium Acetate Injection 2mEq/mL

    22 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250722981335/en/A.forall-Announces-the-Direct-Commercialization-of-Sodium-Acetate-Injection-2mEqmL

    BUSINESSWIRE
    22 Jul 2025
    Share Share
    A.forall Launches Tromethamine Injection With CGT Exclusivity
    A.forall Launches Tromethamine Injection With CGT Exclusivity

    30 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250130954160/en

    BUSINESSWIRE
    30 Jan 2025
    Share Share
    Milla and Alter Announce Yet Another “First Cycle” FDA Approval for Dexmedetomidine Hydrochloride Injection
    Milla and Alter Announce Yet Another “First Cycle” FDA Approval for Dexmedetomidine Hydrochloride Injection

    09 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230609005336/en

    BUSINESSWIRE
    09 Jun 2023
    Share Share
    Milla's Generic Dexmedetomidine HydrochlorideReceives Approval in the U.S.
    Milla's Generic Dexmedetomidine HydrochlorideReceives Approval in the U.S.

    07 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217308

    FDA
    07 Jun 2023
    Share Share
    Milla and the Alter Announce Launch of a Generic Version of Magnesium Sulfate
    Milla and the Alter Announce Launch of a Generic Version of Magnesium Sulfate

    20 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230320005186/en

    BUSINESSWIRE
    20 Mar 2023
    Share Share
    Milla and Alter Group Announce First Paragraph IV Filing and Acceptance by FDA
    Milla and Alter Group Announce First Paragraph IV Filing and Acceptance by FDA

    26 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221026006162/en

    BUSINESSWIRE
    26 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search